因素 | GSU组(22) | 非GSU组(35) | t/c2/Z | p值 |
年龄(岁) | 68.18 ± 6.61 | 66.51 ± 7.13 | −0.884 | 0.381 |
根治活检时间间隔(天) | 21.00 (9.75~46.50) | 18.00 (12.00~41.00) | −0.304 | 0.761 |
BMI (kg/m2) | 26.18 ± 2.53 | 25.65 ± 3.10 | −0.673 | 0.540 |
单核细胞(×109/L) | 0.54 ± 0.18 | 0.48 ± 0.15 | −1.387 | 0.174 |
淋巴细胞(×109/L) | 1.73 ± 0.41 | 1.69 ± 0.64 | −0.283 | 0.778 |
中性粒细胞(×109/L) | 4.05 ± 1.30 | 3.82 ± 1.48 | −0.609 | 0.545 |
NLR | 2.34 (1.83~3.01) | 1.98 (1.39~3.41) | −0.574 | 0.566 |
tPSA (ng/ml) | 15.52 (11.06~29.85) | 9.42 (4.91~16.7) | −2.918 | 0.004 |
fPSA (ng/ml) | 2.17 (1.42~4.00) | 2.14 (1.06~2.96) | −0.959 | 0.338 |
f/tPSA (%) | 0.13 (0.11~0.15) | 0.20 (0.14~0.25) | −2.623 | 0.009 |
PV (ml) | 40.59 (32.64~63.69) | 58.10 (42.68~71.24) | −1.524 | 0.127 |
评分最高针肿瘤组织占比(%) | 50 (28.75~80.00) | 20.00 (10.00~50.00) | −0.3.009 | 0.003 |
活检阳性针数(针) | 3.00 (1.00~6.00) | 2.00 (1.00~5.00) | −1.080 | 0.280 |
PSAD | 0.44 (0.25~0.75) | 0.17 (0.12~0.28) | −3.869 | 0.000 |
临床T分期 |
|
|
|
|
1 | 1 (6.67) | 14 (93.33) | 17.618 | 0.000 |
2 | 12 (37.50) | 20 (62.50) |
|
|
3 | 9 (90.00) | 1 (10.00) |
|
|
民族 |
|
|
|
|
汉族 | 11 (34.38) | 21 (65.62) | 1.927 | 0.387 |
维族 | 8 (53.33) | 7 (46.66) |
|
|
其他 | 3 (30.00) | 7 (70.00) |
|
|
高血压史 |
|
|
|
|
有 | 5 (31.25) | 11 (68.75) | 0.507 | 0.477 |
无 | 17 (41.46) | 24 (58.54) |
|
|
糖尿病史 |
|
|
|
|
有 | 3 (50.00) | 3 (50.00) | 0.027 | 0.870 |
无 | 19 (37.25) | 32 (62.75) |
|
|
内分泌治疗史 |
|
|
|
|
有 | 5 (35.71) | 9 (64.29) | 0.065 | 0.799 |
无 | 17 (39.53) | 26 (60.47) |
|
|